Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
E Van Den Neste, N Schmitz, N Mounier… - Bone marrow …, 2017 - nature.com
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma
(DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of …
(DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of …
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of …
E González-Barca, A Boumendil, D Blaise… - Bone marrow …, 2020 - nature.com
Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for
patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line …
patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line …
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
D Telio, K Fernandes, C Ma, R Tsang… - Leukemia & …, 2012 - Taylor & Francis
Patients with primary refractory diffuse large B-cell lymphoma (REF DLBCL: progression on
or within 3 months of completion of primary therapy) sensitive to salvage chemotherapy …
or within 3 months of completion of primary therapy) sensitive to salvage chemotherapy …
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier… - Bone marrow …, 2016 - nature.com
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the
standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma …
standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma …
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel …
RL Elstrom, P Martin, K Ostrow, J Barrientos… - … Myeloma and Leukemia, 2010 - Elsevier
Background Patients with diffuse large B-cell lymphoma (DLBCL) who are not cured by
initial therapy sometimes experience disease-free survival after autologous stem cell …
initial therapy sometimes experience disease-free survival after autologous stem cell …
The non‐relapse mortality rate for patients with diffuse large B‐cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is …
BT Hill, L Rybicki, BJ Bolwell, S Smith… - British journal of …, 2011 - Wiley Online Library
High dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the
preferred treatment modality for patients with relapsed or refractory diffuse large B‐cell …
preferred treatment modality for patients with relapsed or refractory diffuse large B‐cell …
Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
E Klyuchnikov, U Bacher, T Kroll, TC Shea… - Bone marrow …, 2014 - nature.com
Despite overall improvements in outcomes of patients with diffuse large B cell lymphoma
(DLBCL),∼ 30–40% of patients develop relapsed or refractory disease. For patients with …
(DLBCL),∼ 30–40% of patients develop relapsed or refractory disease. For patients with …
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
C Gisselbrecht, E Van Den Neste - British journal of …, 2018 - Wiley Online Library
Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients
still experience relapses. Salvage chemotherapy followed by autologous stem cell …
still experience relapses. Salvage chemotherapy followed by autologous stem cell …
[HTML][HTML] Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large …
A Sirvent, N Dhedin, M Michallet, N Mounier… - Biology of Blood and …, 2010 - Elsevier
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor
prognosis. However, they may achieve long-term survival by undergoing allogeneic stem …
prognosis. However, they may achieve long-term survival by undergoing allogeneic stem …
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study
L Rigacci, B Puccini, A Dodero, P Iacopino… - Annals of …, 2012 - Springer
Patients who relapse after an autologous hematopoietic stem cell transplantation (SCT)
have a very poor prognosis. We have retrospectively analyzed diffuse large B cell lymphoma …
have a very poor prognosis. We have retrospectively analyzed diffuse large B cell lymphoma …